SciVision Biotech Inc.

The Leading Technology of Hyaluronic Acid ~

Dr. Chun-Chang Chen



DISCLAIMER

SciVision's presentation contains our business operation, finance and sales prognosis which is derived from our existing internal / external data analysis. The future business scheme in this release reflect the current belief of SciVision as of the date of this release, we undertake no obligation to update these forward-looking statements for new information, future events, or otherwise.





Agenda

- 1. Company & Product Overview
- 2. Business Operation
- 3. Strategy & Prospect





Company Profile

- Established
- : 12 November 2001

: NT\$535 Million

- Paid-in Capital
- Industry
- Main Products

- Chairman
- Address

- Hyaluronic acid-based medical device
 Hyaluronic acid-based dermal filler
 - Hyaluronic acid-based viscosupplementation Hyaluronic acid-based absorbable adhesion barrier
- : Mr. Kai-Chen Han
- : 9, South 6th Rd., K.E.P.Z., Kaohsiung 806, Taiwan, R.O.C.
 - 1, South 1th Rd., K.E.P.Z., Kaohsiung 806, Taiwan, R.O.C. (New Factory)





SciVision Snapshot

- Biotechnology Company
- GMP certificate
- ISO13485
- Dermal filler approved by TFDA
 CE and CFDA
- Viscosupplement approved by TFDA and CE
- TIPS





Grants

Obtain Seven SBIR Projects and so on, up to NT\$60M grants from Taiwan Government as the recognition of our outstanding research achievement.





Awards

Five National Industry Innovation Awards from Taiwan Government as the recognition of our outstanding R&D achievement.





ΞŴ	CERTIFICATE	TION MANY AND AND AND	<i>.</i>
	CERTIFICATE OF REGISTRA	ATION	
This is to could had		the sale where the	, e
9. South 6" Rd., K.E.P.J	otech Inc. Z. Kashsung 805, Tawan, R.O.C	and the Paralat	
operates a Outrality Manna	gement System	Sed and an Maler	-
which complies with the	gement System requirements of 03 of registration and Sales of Tissue Augmentati		8
ISO 13485:20 for the following scope of	03 of registration	the state for the state	è.
Supplement for the an	ea of plastic surgery and orthop	sedies,	1
Centificate No.: CERT 00 File No.: 1541766	75952 Original Date M Effective Date M Rapiny Date M	ky 4, 2014 ky 4, 2014 ky 3, 2017	
Chi Ja	the	and the work in the state	
Onin Average Strategies Strategies Lange	Tanie Diast Heat of Pality, Reb and C	all rights were	-
	CHOCKE Management Magazine	200 Anonestination and the	3
	and States		P.
		SAIGLOBAL	
	the local lines which a fight that it is an an and the result	The Property of the second	0
111 400 20	and and	the state when the	
11.29 . 20	Cana		
11.09 50	Cana	da	
	Cana	da	
	Cana	da	
11. 49° 50	Cana	da	
	Cana	da –	1
bsi.			1
bsi. Certifica	te of Regist	tration	1
bsi. Certifica	te of Regist	eration	1
bsi. Certifica	te of Regist	tration	
bsi. Certifica	te of Regist	eration	
bsi. Certifica	te of Regist	eration	
bsi. Certifica Cutifi vande To to to with the Mark Construction	te of Regist terr system - too vent.co software Network - too vent.co software Network - too Software Network - too Software Network - too Software Network - too Network - too Network - too vents of the software Network - too Network - too Ne	eration Market States (States) Market States (States	
bsi. Certifica Cutifi vande To to to with the Mark Construction	te of Regist	eration Market States (States) Market States (States	
bsi. Certifica Cutifi vande To to to with the Mark Construction	te of Regist terr system - too vent.co software Network - too vent.co software Network - too Software Network - too Software Network - too Software Network - too Network - too Network - too vents of the software Network - too Network - too Ne	eration Market States (States) Market States (States	
bsi. Certifica Cutifi vande To to to with the Mark Construction	te of Regist terr system - too vent.co software Network - too vent.co software Network - too Software Network - too Software Network - too Software Network - too Network - too Network - too vents of the software Network - too Network - too Ne	The formation of the second se	
bsi. Certifica Quilty Manage Tata in the other	te of Regist te state of the st	• E = E = E = E = E = E = E	
		erection and a second	
bsi. Certifica QULITY MARACE To to the with the Market of the second sec		erement of District to the function of the state of the	

ISO 9001


인정변호(No.): KTL-868-022001 의료기기 제조 및 품질관리 기준 적합인정서 (Certificate of GMP) GMP HOMA / H 25538 CARENICS · GED (Represent CI M E (Los Sock Jun) · 包括 会形形 (Company address of Applicant 서울특별시 이호구 등드컵로20월 51 (양원동, 대성필당 48) 51, World Cup-ro 29-pl, Mapo-pu, Secul. 121-83 # JIS 4 92 (Name of Ma ■ 制固合 合双双 (Address of Manufactu 9. South 6th Rd.,K.E.P.Z., Kashslung, 80681, Talean, R.O.O. 842 X 50 . W285 ion of Product(s) : See attact 의료기기 제조 및 문질관리기준이 적합함을 인정합니다. a hereby certify that the above manufacture of Manufacturing Practices of Medical Dev (Date of Expiration) | 2017. 04. 17 식 품 의 약 품 안 전 처 장 한국산업기술시 임원장 Korea bsi. Certificate of Registration QUALITY MANAGEMENT SYSTEM - ISO 13485: 2003 & EN ISO 13485:2012 9, South 6th Rd. K.E.P.Z. Kauhsking 806 Talwart HD 621215 nents of 150 (3485-200) & EN 15 Ret Force For and on behalf of \$62

making excellence a habi

ISO 13485

٢

Quality Assurance Certificates



Taiwan





Certificate Awards- Dermal Filler





Product Awards – Viscosupplementation






Core Technology

$(\underline{Crosslinked } \underline{H}yaluronic \underline{A}cid \underline{P}latform, CHAP_{(\mathbb{R})})$

Strong worldwide IP protection for CHAP - Taiwan, China, Japan and USA





Patents



Taiwan

EU patent is under review.



Japan








Product Overview – Dermal Filler

<section-header>

Dermal fillers help to diminish facial lines and restore volume and fullness in the face Hyaluronic Acid, Global



- 1. Global market value up to US\$1.2 billion in 2015
- 2. CAGR:12%



Leading Technology For Hyaluranic Acid

Source : GlobalData



Product Advantages



HYADERMIS/ FACILLE

- 1. We offer a full range of dermal fillers, that meet various individual needs and specific requirements for facial aesthetic enhancements. There are reports to show long-lasting results.
- 2. Provide supreme quality with competitive prices, aiming to enlarge market share.
- 3. Channeling existing brands via Galderma's platforms and further growing rapidly up in the global market.



400,000+ Syringes used worldwide Accounts coverage : 300+ aesthetics clinics in Taiwan






Healthcare - Viscosupplementation

HA Viscosupplementation



The products are indicated for the treatment of degenerative osteoarthritis via intra-articular injection to help minimize joint pains and improve joint mobility.



1. Global HA

viscosupplementation market up to US\$2.3 billion in 2015

2. CAGR:7.5%

Source: GlobalData



15



HYAJOINT'Plus

海捷特。加强亚霸简腔注射和





HYAJOINT/ HYVISC

 Treatment: up to 6 months pain relief and fewer visits to physicians
 Price: more cost-effective



3 million+ syringes used worldwide Accounts coverage : 450+ clinics & 17 hospitals in Taiwan Account for 50%+ market share in Taiwan






Involving Surgery - Absorbable Adhesion Barrier

Absorbable Adhesion Barrier



The hyaluronic acid-based gel for the prevention of postsurgical adhesions. This product has larger Chinese market because of higher rate of caesarean section.

Anti-Adhesion Products Market, Global



- 1. Global market value up to US\$2.1 billion in 2015
- 2. CAGR : 8.9%

Source: GlobalData



17



Product Advantages

PROTAHERE Absorbable Adhesion Barrier



玻達癒 可吸收防沾黏凝膠

PROTAHERE Absorbable Adhesion Barrier

This product, a good viscosity, fluidity and high degree of biocompatibility of the gel, can be attached completely to the surface of the tissue and form a barrier, not move with the patient's movements. It can form an effective layer to reduce the probability of post-operative adhesion.







Agenda

1. Company & Product Overview


2. Business Operation

3. Strategy & Prospect






Sales breakdown by geography





Sales breakdown by product

• Year 2014~2015 & 2016/1~11





Partnering with the Leading International Brand-Nestle

SciVision & Nestle signed an Exclusive Distribution Agreement to Collaborate in China for FACILLE Dermal Filler Distribution.

The most valuable brands of 2015

Rank	Brand	Age	Country
1	Google	17	USA
2	Apple	39	USA
3	Amazon	20	USA
4	GE	123	USA
5	Samsung	77	South Korea
б	Walmart	53	USA
7	Nike	43	USA
8	Mercedes-Benz	115	Germany
9	Facebook	11	USA
10	Nestle	148	Switzerland

Galderma, Nestle's subsidiary, an international dermatology company, is dedicated to innovating skin disease solutions & aesthetic & corrective products. Its extensive product portfolio is available in 80 countries. Its product, Restylane, has No.1 distribution network in China.



22

http://www.worldbrandlab.com/world/2015/



Agenda

1. Company & Product Overview

2. Business Operation

3. Strategy & Prospect





Business Strategy



Technology focus in Taiwan and forward to Global



24



Advantages & Opportunity



- 1. In-house Know-How
- 2. Worldwide Patents of CHAP

Opportunity

3. Good Quality



Follow with Nestle's cooperation, alliances among international brands with different products.



Expanding to Meet Growing Demand

- **The new factory will cover a total floor space of approximately 19,781.85 m²**
- The new plant and facilities are designed to meet the requirements by cGMP, GEP, GAMP, ISPE, US FDA, and PIC/s GMP.
- Annual capacity of medical devices is 12M pre-filled syringes.
- Annual capacity for CMO is 23M pre-filled syringes.





Building layout drawing in 2014






Contract Manufacture Organization (CMO)

Contract Manufacture Organization (CMO)

Manufacturing services offered, with volume capabilities ranging from small amount for preclinical R&D to larger volume necessary for clinical trial purposes and commercialization



CMO Market, Global

- 1. Global market value up to US\$50.1 billion in 2015
- 2. CAGR : 12%

Source : BusinessInsights



27



Short-term and Long-term Plans

Short-term Plans :

- 1. Alliances with Nestle for global dermal filler market
- 2. New plant launch for operation
- 3. Absorbable Adhesion Barrier approved by TFDA and CFDA
- 4. Single-injection viscosupplement approved by US FDA
- 5. Branch out into CMO business

Long-term Plans :

- 1. Single-injection viscosupplement approved by CFDA
- 2. Other technology cross-link developed with hyaluronic acid
- 3. No.1 medical device contract manufacturer in Asia



Vision & Prospect

Vision



Prospect

Leading HA brand in the world

The best choice in global market





